About Elucid
Elucid is an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions. The company's flagship product, Plaque-IQ, is the first and only FDA-cleared, non-invasive plaque analysis based on objective ground-truth histology rather than subjective CCTA visual estimates. Developed in partnership with world-renowned cardiovascular pathologists, Plaque-IQ quantifies and classifies plaque morphology including lipid-rich necrotic core, calcified, and non-calcified components at the patient, vessel, and lesion level. The technology addresses a critical gap in cardiovascular diagnostics: while about half of Americans between ages 45 and 84 have atherosclerosis, many don't know it, and current diagnostics miss key information about plaque type and composition. Elucid's CT Virtual Histology technology enables physicians to understand plaque tissue histology through non-invasive testing, supporting clinical decisions around intervention versus drug therapy and helping to prevent heart attacks and strokes. The company serves cardiologists, radiologists, and cardiovascular specialists across health systems and has achieved significant commercial milestones including Category I CPT code designation and broad CMS reimbursement. Elucid is also developing FFR CT capabilities that leverage histology-based plaque composition for lesion-level fractional flow reserve measurements.
Clinical Focus
Medical conditions and clinical areas addressed by Elucid.
Who It Serves
Milestones & Awards
Recent Milestones
Won 'Best New Cardiology Technology Solution' in 2026 MedTech Breakthrough Awards (May 2026). Launched Lesion Inspection Tool (April 2026). Achieved Category I CPT code designation (January 2026). Gained broad CMS reimbursement (December 2025). Launched carotid artery analysis capability (October 2025). Secured United Healthcare coverage (August 2025). Appointed Dr. Robert Pelberg as SVP Medical Affairs (July 2025).
Awards & Recognition
Best New Cardiology Technology Solution - 2026 MedTech Breakthrough Awards
Key Partnerships
Social & Media
Follow on
Latest Updates
Elucid Announces Broad Reimbursement for Quantitative Coronary Plaque Analysis
Elucid Names Richard E. Kuntz, MD, MSc and Shamiram Feinglass, MD, MPH Board Directors
Elucid’s PlaqueIQ Image Analysis Software Included in EviCore Coverage Guidelines
Elucid Gains Broad CMS Reimbursement of Coronary Plaque Analysis Using PlaqueIQ™
Elucid Names Richard E. Kuntz, MD, MSc and Shamiram Feinglass, MD, MPH Board Directors
Company Details
- Headquarters
- Boston, MA, USA
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSimilar Companies in this Market
View all 64 →
AccurKardia
AI-powered platform for cardiovascular disease detection and cardiac risk assessment.
Acorai
AI platform for cardiovascular disease detection and cardiac risk assessment.
Aisap
11-50 employees
AISAP provides FDA-cleared AI-powered diagnostic algorithms embedded in an operating system for point-of-care ultrasound (POCUS) devices. The platform enables rapid, expert-level cardiac imaging interpretation at the bedside, helping physicians detect structural heart disease early and make faster clinical decisions across hospitals, clinics, and screening programs.
AliveCor
AliveCor develops FDA-cleared, AI-powered ECG devices and software platforms for cardiac monitoring. The company offers portable ECG solutions ranging from consumer personal devices to clinical-grade 12-lead systems, serving patients, healthcare providers, biopharma companies, and health systems with remote and connected cardiac care.
Anumana AI
series c · 175 employees
Anumana AI develops and delivers AI-driven ECG algorithms to enable early diagnosis and intervention for cardiovascular conditions.
Artrya
11-50 employees
Artrya develops AI-powered solutions for rapid assessment of chest pain patients in emergency and primary care settings. The company's technology analyzes coronary computed tomography angiography (CCTA) to detect arterial plaque and stratify patient risk within minutes.
Bay Labs
Bay Labs is a health AI company focused on cardiology and cardiovascular health. The company's website is currently under construction with limited public information available.
BunkerHill Health
Bunkerhill Health provides Carebricks, an AI-powered platform that enables health systems to design, deploy, and operationalize AI agents across clinical and operational workflows. The platform reasons across patient data and automates actions within existing EHR systems.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.